Jefferies Financial Group Inc. Takes $749,000 Position in Vanda Pharmaceuticals Inc. $VNDA

Jefferies Financial Group Inc. acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 122,427 shares of the biopharmaceutical company’s stock, valued at approximately $749,000. Jefferies Financial Group Inc. owned about 0.20% of Vanda Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Royal Bank of Canada grew its position in Vanda Pharmaceuticals by 34.3% during the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 14,232 shares during the last quarter. Millennium Management LLC increased its stake in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Hsbc Holdings PLC raised its holdings in shares of Vanda Pharmaceuticals by 17.6% in the second quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 9,960 shares during the last quarter. Norges Bank purchased a new position in shares of Vanda Pharmaceuticals in the second quarter worth $543,000. Finally, Walleye Capital LLC lifted its stake in shares of Vanda Pharmaceuticals by 155.1% during the second quarter. Walleye Capital LLC now owns 94,298 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 57,332 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $5.29 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60. The company’s fifty day moving average price is $5.56 and its 200-day moving average price is $6.49. Vanda Pharmaceuticals Inc. has a 1-year low of $4.27 and a 1-year high of $9.94. The firm has a market capitalization of $319.85 million, a P/E ratio of -1.14 and a beta of 0.64.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -3 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on VNDA. B. Riley Financial reissued a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Finally, HC Wainwright cut their price objective on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vanda Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $13.70.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.